The FDA has issued new draft guidance on how biologic product sponsors should address postapproval changes in chemistry, manufacturing, and controls.
The FDA has issued new draft guidance on how biologic product sponsors should address postapproval changes in chemistry, manufacturing, and controls (CMC).
The draft guidance, prepared by the Office of Pharmaceutical Quality in the Center for Drug Evaluation and Research, provides recommendations to biologics license application (BLA) holders regarding the types of changes to an approved BLA that can be documented in annual reports. Under FDA regulation, postapproval CMC that have a minimal potential to affect product quality can be documented by BLA holders on a yearly basis, while changes that are considered major require applicants to submit and receive FDA approval of a supplement to the BLA before the affected product can be distributed. Moderate changes require a supplement to be submitted 30 days before product distribution.
The list of CMC changes to be submitted annually include:
If the FDA determines that a CMC change that falls into one of these categories would be more appropriately categorized as a major or moderate change and therefore require a supplement, the FDA will notify the applicant and request further information.
Changes documented in annual reporting should include full descriptions, with details concerning the manufacturing sites involved, the date of the change, a cross-reference relevant to validation protocols or standard operating procedures, relevant data from studies and tests performed to assess the effect of the change on product quality, a list of products involved, and a statement that the effects of the change have been assessed.
The FDA notes that it has produced the new guidance after having observed a steady increase in the number of CMC manufacturing supplements that it has received. An annual submission of CMC changes that have a minimal potential to harm product quality could allow the agency to streamline its processes, in keeping with its current focus on efficiency and the better use of limited resources.
The FDA will accept comments on the draft guidance on docket FDA-2017-D-2802 until October 10, 2017.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
November 26th 2024The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.